2025-10-20 - Analysis Report
Okay, here's an analysis of UnitedHealth Group Inc. (UNH) based on the data you provided, formatted as a report with key numbers, analysis, and considerations:

**Report: UnitedHealth Group Inc. (UNH) Analysis**

**1. Relative Performance & Company Overview**

*   **Ticker:** UNH
*   **Company:** UnitedHealth Group Inc. - A diversified healthcare company providing a wide range of healthcare products and services.

*   **Key Numbers:**
    *   UNH Cumulative Return: -17.06%
    *   S&P 500 (VOO) Cumulative Return: 97.05%
    *   Absolute Divergence (UNH - VOO): -114.11%
    *   Divergence Range (Max: 36.3, Min: -130.7)
    *   Relative Divergence: 9.9
        *   *This means the current divergence is near the low end of its historical range relative to the S&P 500.*

*   **Analysis:** UNH has significantly underperformed the S&P 500.  The relative divergence indicates this underperformance is near the lowest end of its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2015-2017  | 58.0%  | 66.4% | 30.0%  | 0.1  | 199.7  |
| 2016-2018  | 41.0%  | 70.4% | 26.0%  | 0.1  | 225.6  |
| 2017-2019  | 36.0%  | 73.8% | 14.0%  | 0.2  | 266.2  |
| 2018-2020  | -43.0% | 81.2% | -67.0% | 0.5  | 317.6  |
| 2019-2021  | 16.0%  | 81.2% | -30.0% | 1.5  | 454.8  |
| 2020-2022  | -1.0%  | 81.2% | 0.0%   | 1.5  | 480.2  |
| 2021-2023  | 24.0%  | 80.8% | 23.0%  | 0.4  | 476.8  |
| 2022-2024  | -27.0% | 78.8% | -47.0% | 0.3  | 458.1  |
| 2023-2025  | -60.0% | 78.9% | -121.0%| 1.2  | 323.0  |

*   **Analysis:**
    *   **CAGR:**  Shows declining growth rates in recent periods.
    *   **MDD:** High Maximum Drawdown values, indicating significant price volatility.
    *   **Alpha:**  In recent periods, negative Alpha indicates underperformance relative to the benchmark.
    *   **Beta:** Beta values vary significantly, suggesting changing correlation and volatility relative to the market. Beta has been elevated in recent years.
    *   **Cap(B):** Market capitalization has decreased drastically the lastest years.

**2. Recent Price Action**

*   **Current Price:** 356.60
*   **Last Market Data:**
    *   Price: 356.6
    *   Previous Close: 356.67
    *   Change: -0.02
*   **Moving Averages:**
    *   5-day MA: 358.60
    *   20-day MA: 354.11
    *   60-day MA: 315.99

*   **Analysis:**
    *   The price is slightly down compared to the previous close.
    *   The price is below the 5-day moving average but above the 20-day and 60-day moving averages.  This suggests short-term downward momentum but longer-term upward trend.
    *   The 20-day moving average approaching the 60-day could signal a change in trend.

**3. Technical Indicators & Hybrid Signal**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 59.55 (Approaching overbought territory)
*   **PPO:** -0.55
*   **Hybrid Signal:** cash_79%_Sell (Sell 79.7% of holdings)
*   **Recent (20-day) Relative Divergence Change:** -1.9 (Negative - short-term decline)
*   **Expected Return:** -135.0%

*   **Analysis:**
    *   MRI suggests low investment risk, but still requires caution.
    *   RSI is approaching overbought territory, suggesting potential for a pullback.
    *   The negative PPO suggests a bearish trend.
    *   The Hybrid Signal recommends a significant reduction in holdings.
    *   The negative change in relative divergence indicates recent underperformance compared to the S&P 500.
    *   The very negative expected return suggests significant potential underperformance compared to the S&P 500 over the long term.
    *   The price change from the "Last-market" data isn't significant enough to indicate a major volatility event.

**4. Recent News & Significant Events**

*   **[2025-10-18] Goldman Sachs Initiates Coverage with a Buy Rating:** Positive signal, but needs to be considered in context.
*   **[2025-10-17] CEO Role Split Proposal:**  Uncertainty regarding leadership structure can impact investor confidence.
*   **[2025-10-17] Medicare Part D Overspending:**  Potential regulatory or competitive pressures impacting revenue.
*   **[2025-10-17] CVS/Rite Aid Acquisition:**  Increased competition in the healthcare services landscape.
*   **[2025-10-17] Jefferies Adjusts Price Target Upward:**  Positive signal, but consider the reasoning behind the adjustment.
*   **[2025-10-16] UNH Registers a Bigger Fall Than the Market:** Reinforces recent underperformance concerns.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.93)
*   **Opinions:** 25
*   **Target Price:**
    *   Average: 372.04
    *   High: 626.00
    *   Low: 198.00

*   **Analysis:** Analyst consensus is generally positive, but there is a very wide range in price targets, indicating uncertainty in valuation.

**5. & 6. Earnings and Financial Information**

*   **Recent Earnings (Quarterly):**

| 날짜       | EPS   | 매출 (B$) |
|------------|-------|------------|
| 2025-08-11 | 3.76  | 111.62     |
| 2025-05-07 | 6.9   | 109.58     |
| 2024-11-04 | 6.56  | 100.82     |
| 2024-08-09 | 4.58  | 98.86      |
| 2025-08-11 | 4.58  | 98.86      |

* **Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $111.62B | 17.93%        |
| 2025-03-31 | $109.58B | 21.70%        |
| 2024-12-31 | $100.81B | 21.14%        |
| 2024-09-30 | $100.82B | 22.84%        |
| 2024-06-30 | $98.86B  | 22.31%        |

* **Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $94.72B  | 3.60%   |
| 2025-03-31 | $95.04B  | 6.62%   |
| 2024-12-31 | $92.66B  | 5.98%   |
| 2024-09-30 | $94.53B  | 6.41%   |
| 2024-06-30 | $89.36B  | 4.72%   |

*   **Analysis:**
    *   Revenue has been growing. However, Profit Margin and ROE has been decreasing the lastest year.

**7. Summary & Considerations**

*   **Overall:** UNH is showing signs of weakness. It is underperforming the market, with concerning technical indicators and a negative expected return.
*   **Positives:** Analyst consensus remains positive, and revenue is growing.
*   **Negatives:** Significant underperformance, decreasing profit margins, potentially concerning news events, and a negative hybrid signal all raise red flags.
*   **Considerations:**
    *   The healthcare sector is subject to regulatory and political changes.
    *   Competition is increasing within the industry.
    *   Monitor the CEO role split proposal and its impact on the company's strategy.
*   **Recommendation:** Based on this analysis, a cautious approach is warranted. The Hybrid Signal suggests reducing holdings. Further research and monitoring of the company's performance and news are recommended before making any investment decisions. The very negative expected return should be a major concern for long-term investors.
